Krazati FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 27, 2022.
FDA Approved: Yes (First approved December 12, 2022)
Brand name: Krazati
Generic name: adagrasib
Dosage form: Tablets
Company: Mirati Therapeutics, Inc.
Treatment for: Non-Small Cell Lung Cancer
Krazati (adagrasib) is a small-molecule inhibitor of KRAS G12C for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Krazati works as a targeted therapy by inhibiting KRAS G12C to suppress tumor growth in patients with KRAS G12C-mutated non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery, and who have received at least one prior treatment.
- Krazati tablets are taken orally, twice daily, with or without food.
- Warnings and precautions associated with Krazati include gastrointestinal adverse reactions, QTc interval prolongation, hepatotoxicity, and interstitial lung disease / pneumonitis.
- Common adverse reactions include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite.
Common laboratory abnormalities include decreased lymphocytes, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, decreased leukocytes, decreased neutrophils and increased alkaline phosphatase.
Development timeline for Krazati
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
